



The National Institute for Occupational Safety and Health (NIOSH)

Promoting productive workplaces
through safety and health research **NIOSH**

Hazardous Drugs: Draft NIOSH List of Hazardous Drugs in Healthcare Settings, 2024; Procedures; and Risk Management Information

NIOSH DOCKET NUMBER 233-C, CDC-2020-0046

MAY 2020

This docket includes the activities of the National Institute for Occupational Safety and Health (NIOSH) associated with updating the *NIOSH List of Hazardous Drugs in Healthcare Settings* from 2020 through 2024. Specifically, on May 1, 2020, NIOSH announced draft documents available for public comment: (1) *NIOSH Procedures for Developing the NIOSH List of Hazardous Drugs in Healthcare Settings (Procedures)*; (2) *NIOSH List of Hazardous Drugs in Healthcare Settings, 2020*, including those drugs proposed for placement on the 2020 List, and (3) *Managing Hazardous Drug Exposures: Information for Healthcare Settings*. On April 27, 2023 NIOSH announced the final publication of the *Procedures* and *Managing Hazardous Drug Exposures: Information for Healthcare Settings*. On January 16, 2024, NIOSH requested public comment on two draft reevaluations of two listed drugs, liraglutide and pertuzumab. Finally, a FRN published on December 20, 2024 announces the publication of the *NIOSH List of Hazardous Drugs in Healthcare Settings, 2024*, responds to public comment on the 2020 publication, and announces the removal of liraglutide and pertuzumab from the List.

To view the notice and related materials, visit <http://www.regulations.govexternal>  and enter CDC-2020-0046 in the search field and click "Search."

Reference Documents

- **Federal Register Notice:** [Federal Register Notice 12-20-2024](#)  [PDF – 400 KB]
- **Federal Register Notice:** [Federal Register Notice 1-16-2024](#)  [PDF – 203 KB]
- **Federal Register Notice:** [Federal Register Notice 4-27-2023](#)  [PDF – 309 KB]
- **Federal Register Notice:** [Federal Register Notice 6-19-2020](#)  — **Extension of Comment Period**
- **Federal Register Notice:** [Federal Register Notice 5-1-2020](#) 
- **Background Information:**
 - [NIOSH Procedures for Developing the NIOSH List of Hazardous Drugs in Healthcare Settings](#) 
 - [Draft NIOSH Procedures for Developing the NIOSH List of Hazardous Drugs in Healthcare Settings](#)  [PDF – 897 KB]
 - **Final** – [NIOSH List of Hazardous Drugs in Healthcare Settings, 2024](#)  [PDF – 419 KB]
 - [Draft NIOSH List of Hazardous Drugs in Healthcare Settings, 2020](#) 
 - [Managing Hazardous Drug Exposures: Information for Healthcare Settings](#) 
 - [Draft Managing Hazardous Drug Exposures: Information for Healthcare Settings](#)  [PDF – 4 MB]
 - [NIOSH Final Reevaluation Determination of Pertuzumab on the NIOSH List of Hazardous Drugs in Healthcare Settings](#)  [PDF – 281 KB]
 - [Draft NIOSH Reevaluation of Pertuzumab on the NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings](#)  [PDF – 248 KB]
 - [NIOSH Final Reevaluation Determination of Liraglutide on the NIOSH List of Hazardous Drugs in Healthcare Settings](#)  [PDF – 216 KB]

- [Draft NIOSH Reevaluation of Liraglutide on the NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings](#)  [PDF – 185 KB]

Peer Review: *Managing Hazardous Drug Exposures: Information for Healthcare Settings*

Subject of Planned Report: This dissemination describes the health and safety risks associated with exposure to hazardous drugs in healthcare settings, and discusses methods to control those risks.

Purpose of Planned Report: The dissemination will inform workers and managers in healthcare workplaces, including healthcare professionals, administrative workers, and environmental control staff, of the potential risks associated with exposure to hazardous drugs, how to recognize the presence of hazardous drugs, and how to properly label, handle and store hazardous drugs.

Type of Dissemination: Influential Scientific Information.

Timing of Review: 05/01/2020 to 08/01/2020

Type of Review: Individual letter reports.

Opportunities for the Public to Comment: Yes

Comment period announced via Federal Register Notice. Public comment period concurrent with peer review. Comments may be submitted by any of the following methods:

- [Federal eRulemaking Portal](#)  : Follow the instructions for [submitting comments](#)  .
- [NIOSH Docket](#)
- Mail: National Institute for Occupational Safety and Health, NIOSH Docket Office, 1090 Tusculum Avenue, MS C-34, Cincinnati, Ohio 45226-1998.

Peer Reviewers Provided with Public Comments Before the Review: No

Anticipated Number of Reviewers: 4 – 10

Primary Disciplines or Expertise: Industrial hygiene, engineering, occupational safety and health

Reviewers Selected By: NIOSH

Public Nominations Requested for Reviewers: No

Charge to Peer Reviewers:

1. Please provide feedback on the overall document:
 - a. What additional information would improve its usefulness and why?
 - b. What changes could be made to improve the utility of the information?
 - c. What information is redundant, incorrect, missing, or not needed? Please explain.
2. Please provide any additional studies or scientific information that evaluate or validate engineering, work practice or administrative controls to reduce exposures to hazardous drugs in healthcare settings.
3. Please provide any additional studies or scientific information that support or validate the use of the NIOSH recommended control strategies or alternative strategies to control exposures to hazardous drugs.
4. Please provide any additional studies or scientific information that support or validate evidence-based strategies or approaches for controlling exposures to hazardous drugs that are different from those that NIOSH has proposed.

5. NIOSH has provided its proposed recommendations and related information about controlling hazardous drugs in the Table of Control Approaches in Chapter 8.
 - a. What additional information would improve the usefulness of this table and why?
 - b. What structural or format changes could be made to improve the utility of this table?
 - c. What information is redundant, incorrect, missing, or not needed? Please explain.
6. What improvements could be made to this risk management information to make it more useful to employers and healthcare workers? Please provide specific examples.
7. Please provide information about your professional experience, if any, of implementing control strategies for exposures to hazardous drugs in healthcare or similar settings. Please describe what you found to be most or least effective and why. Include relevant publications if available.
8. Please provide any additional comments or suggestions either as a list below or using Track Changes in the attached draft document.

Last Reviewed: August 3, 2020

 Was this page helpful?

Yes Partly No